Press release
Severe Hypertriglyceridemia Pipeline Insight 2023 (Updated) | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, and Others
The report titled "Severe Hypertriglyceridemia Pipeline Insight 2023" by DelveInsight offers extensive information on more than 10+ companies and 10+ pipeline drugs in the field of Severe Hypertriglyceridemia. It presents detailed profiles of these drugs, encompassing both Severe Hypertriglyceridemia clinical trials and nonclinical stage products. The Severe Hypertriglyceridemia pipeline report also includes a thorough assessment of therapeutics based on product type, stage, route of administration, and molecule type. Additionally, it highlights the inactive pipeline products in this area.The Severe Hypertriglyceridemia Pipeline report provides an elaborate account of the drug, encompassing its mechanism of action, Severe Hypertriglyceridemia clinical trials studies, Severe Hypertriglyceridemia NDA approvals (if any), and product development endeavors such as technology advancements, collaborations pertaining to Severe Hypertriglyceridemia, licensing, mergers and acquisitions, funding, designations, and other relevant details concerning the product.
To explore more information on the latest breakthroughs in the Severe Hypertriglyceridemia Pipeline treatment landscape of the report, click here @ Severe Hypertriglyceridemia Pipeline Outlook- https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Severe Hypertriglyceridemia Pipeline Report
• Over 10+ Severe Hypertriglyceridemia companies are evaluating 10+ Severe Hypertriglyceridemia pipeline therapies in various stages of development, and their anticipated acceptance in the Severe Hypertriglyceridemia market would significantly increase market revenue.
• The leading Severe Hypertriglyceridemia companies are working in the market such as Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others
• Promising Severe Hypertriglyceridemia Pipeline Therapies in various stages of development include Pegozafermin, Olezarsen, Ethyl Icosapentate, K-877, Fenofibrate, omefas, CaPre, and others
• Regeneron Pharmaceuticals' evinacumab was approved under the brand name Evkeeza by FDA in February 2021 for homozygous familial hypercholesterolemia. Regeneron Pharmaceuticals' Evinacumab (also known as REGN1500) is an intravenous ANGPTL-3 Antibody. A recent Phase II trial showed monoclonal antibody evinacumab significantly reduced fasting triglycerides in patients with severe hypertriglyceridemia with acute pancreatitis. Evinacumab binds to angiopoietin-like protein 3 (ANGPTL3), a protein thought to play a role in cholesterol metabolism, inhibiting its function.
• Vupanorsen is an investigational antisense therapy by Pfizer for potential SHTG. Vupanorsen acts through a novel mechanism, targeting ANGPTL3, a genetically validated target of lipoprotein metabolism. Vupanorsen was developed using Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform. In a Phase 2a study, vupanorsen met the primary endpoint of significant reductions in TG levels and multiple secondary endpoints compared to placebo, with a favorable safety and tolerability profile.
Severe Hypertriglyceridemia Overview
Hypertriglyceridemia is a common condition, which is defined as having a high level (above 150 mg/dL) of triglycerides, a type of fat, in the bloodstream. Hypertriglyceridemia can lead to conditions including atherosclerosis (hardening of the arteries), obesity, and insulin resistance, which all can contribute to an increased risk of cardiovascular disease (CVD).
For further information, refer to the detailed Severe Hypertriglyceridemia Unmet Needs, Severe Hypertriglyceridemia Market Drivers, and Severe Hypertriglyceridemia Market Barriers, click here for Severe Hypertriglyceridemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Severe Hypertriglyceridemia Emerging Drugs Profile
• ARO-APOC3: Arrowhead Pharmaceuticals
• Olezarsen: Ionis Pharmaceuticals
Severe Hypertriglyceridemia Pipeline Therapeutics Assessment
There are approx. 10+ Severe Hypertriglyceridemia companies are developing Severe Hypertriglyceridemia therapies. The Severe Hypertriglyceridemia companies which have their Severe Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Ionis Pharmaceuticals, Inc.
Request a sample and discover the recent advances in Severe Hypertriglyceridemia Ongoing Clinical Trial Analysis and Medications, click here @ Severe Hypertriglyceridemia Treatment Landscape- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Severe Hypertriglyceridemia Pipeline Therapeutics Assessment
• Severe Hypertriglyceridemia Assessment by Product Type
• Severe Hypertriglyceridemia by Stage and Product Type
• Severe Hypertriglyceridemia Assessment by Route of Administration
• Severe Hypertriglyceridemia by Stage and Route of Administration
• Severe Hypertriglyceridemia Assessment by Molecule Type
• Severe Hypertriglyceridemia by Stage and Molecule Type
Some of the companies in the Severe Hypertriglyceridemia Therapeutics Market include-
Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others
Dive deep into rich insights for drugs for the Severe Hypertriglyceridemia Pipeline, click here @ Severe Hypertriglyceridemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Severe Hypertriglyceridemia Pipeline Report
• Coverage- Global
• Severe Hypertriglyceridemia Companies- Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, and others
• Severe Hypertriglyceridemia Pipeline Therapies- Pegozafermin, Olezarsen, Ethyl Icosapentate, K-877, Fenofibrate, omefas, CaPre, and others
• Severe Hypertriglyceridemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Severe Hypertriglyceridemia Mergers and acquisitions, Severe Hypertriglyceridemia Licensing Activities @ Severe Hypertriglyceridemia Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/severe-hypertriglyceridemia-shtg-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Severe Hypertriglyceridemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Severe Hypertriglyceridemia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Olezarsen: Ionis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ARO-APOC3: Arrowhead Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Severe Hypertriglyceridemia Key Companies
21. Severe Hypertriglyceridemia Key Products
22. Severe Hypertriglyceridemia- Unmet Needs
23. Severe Hypertriglyceridemia- Market Drivers and Barriers
24. Severe Hypertriglyceridemia- Future Perspectives and Conclusion
25. Severe Hypertriglyceridemia Analyst Views
26. Severe Hypertriglyceridemia Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Severe Hypertriglyceridemia Pipeline Insight 2023 (Updated) | Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, and Others here
News-ID: 3162891 • Views: …
More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…

Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…

Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…

Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Hypertriglyceridemia
Hypertriglyceridemia Market is expected to reach USD 39 billion by 2034
Hypertriglyceridemia is a common lipid disorder characterized by elevated levels of triglycerides in the blood, often associated with obesity, diabetes, metabolic syndrome, and genetic predisposition. While mild to moderate hypertriglyceridemia is widespread, severe cases can lead to acute pancreatitis, cardiovascular disease, and liver complications. The condition is both a standalone metabolic issue and a risk factor for a broader spectrum of chronic diseases.
Download Full PDF Sample Copy of Market Report…
Severe Hypertriglyceridemia Market is expected to reach USD 8.9 billion by 2034
Severe hypertriglyceridemia, defined by triglyceride levels exceeding 500 mg/dL, is a serious metabolic condition linked to an elevated risk of cardiovascular disease, pancreatitis, and liver complications. As obesity, sedentary lifestyles, and diabetes become more prevalent worldwide, the burden of hypertriglyceridemia is rising rapidly. This has created a significant demand for effective pharmacological treatments, dietary interventions, and lifestyle management solutions.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72003
According to Exactitude…
Severe Hypertriglyceridemia Treatment Drugs, Pipeline Insights, Emerging Therapi …
DelveInsight's, "Severe Hypertriglyceridemia Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Severe Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Severe…
Hypertriglyceridemia Therapeutics Market Detailed In New Research Report 2024 |S …
The most recent report published by CMI indicates that the "Hypertriglyceridemia Therapeutics Market 2024-2031" is likely to accelerate significantly in the next few years. The Hypertriglyceridemia Therapeutics Market report gives a purposeful depiction of the area by the practice for research, amalgamation, market size, overview, and review of data taken from various sources. The Hypertriglyceridemia Therapeutics Market study includes information on market factors such as the market dynamics, drivers, restraints,…
Navigating Hypertriglyceridemia: Causes, Risks, and Effective Management Strateg …
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…
Hypertriglyceridemia: Unraveling the Highs and Lows of Triglyceride Metabolism
Hypertriglyceridemia is a common disorder or condition wherein the triglyceride levels in the blood are higher. The growing triglyceride levels are mostly associated with atherosclerosis and cardiovascular diseases (CVDs). This condition also causes pancreatitis, atherosclerosis, and other CVDs. Hypertriglyceridemia is generally worsened or caused by numerous factors such as sedentary lifestyle, poorly controlled diabetes, and obesity. Corneal arcus, xanthelasmas, memory loss, difficulty breathing, dementia, and gastrointestinal pain are typical symptoms…